China Biologic Products (NASDAQ:CBPO) was upgraded by stock analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a research report issued to clients and investors on Tuesday.

Separately, Zacks Investment Research lowered China Biologic Products from a “hold” rating to a “sell” rating in a research note on Monday, January 29th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average target price of $137.50.

Shares of China Biologic Products (CBPO) opened at $79.95 on Tuesday. China Biologic Products has a 12 month low of $72.21 and a 12 month high of $120.46. The firm has a market capitalization of $2,620.00, a P/E ratio of 20.82, a PEG ratio of 1.00 and a beta of 1.67.

Hedge funds have recently added to or reduced their stakes in the company. Comgest Global Investors S.A.S. grew its stake in shares of China Biologic Products by 135.0% in the 3rd quarter. Comgest Global Investors S.A.S. now owns 356,252 shares of the biopharmaceutical company’s stock valued at $32,872,000 after purchasing an additional 204,649 shares during the period. JPMorgan Chase & Co. bought a new stake in shares of China Biologic Products in the 3rd quarter valued at approximately $795,000. Bank of New York Mellon Corp grew its stake in shares of China Biologic Products by 30.1% in the 3rd quarter. Bank of New York Mellon Corp now owns 762,784 shares of the biopharmaceutical company’s stock valued at $70,380,000 after purchasing an additional 176,325 shares during the period. Goldman Sachs Group Inc. grew its stake in shares of China Biologic Products by 4.9% in the 2nd quarter. Goldman Sachs Group Inc. now owns 61,404 shares of the biopharmaceutical company’s stock valued at $6,945,000 after purchasing an additional 2,845 shares during the period. Finally, Wasatch Advisors Inc. grew its stake in shares of China Biologic Products by 66.1% in the 4th quarter. Wasatch Advisors Inc. now owns 228,373 shares of the biopharmaceutical company’s stock valued at $17,989,000 after purchasing an additional 90,891 shares during the period. Institutional investors own 52.44% of the company’s stock.

TRADEMARK VIOLATION WARNING: This article was originally published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this article on another website, it was stolen and republished in violation of United States & international copyright law. The legal version of this article can be read at https://theolympiareport.com/2018/02/13/china-biologic-products-cbpo-upgraded-at-bidaskclub.html.

About China Biologic Products

China Biologic Products Holdings, Inc is a biopharmaceutical company. The Company is principally engaged in the research, development, manufacturing and sales of human plasma-based biopharmaceutical products in China. It operates through the manufacture and sales of human plasma products segment. China Biologic has a product portfolio with over 20 various dosage forms of plasma products and other biopharmaceutical products across nine categories.The Company’s products include human albumin, human immunoglobulin, immunoglobulin for intravenous injection (IVIG), human hepatitis B immunoglobulin, human rabies immunoglobulin, human tetanus immunoglobulin, placenta polypeptide, Factor VIII and human prothrombin complex concentrate (PCC).

Receive News & Ratings for China Biologic Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products and related companies with MarketBeat.com's FREE daily email newsletter.